Gilead & Merck’s Phase 2 Data Show Promise for Oral Weekly HIV Regimen
Gilead Sciences and Merck (MSD outside the U.S. and Canada) have shared promising Phase 2 clinical study results for...
Gilead & Merus Team Up for Groundbreaking T-Cell Engagers
Gilead Sciences, Inc. and Merus N.V. have entered into a research collaboration to develop novel dual tumor-associated antigen (TAA)...
EU Validates Datopotamab Apps for Lung & Breast Cancer
The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan,...
Real-World Data Back Veklury for Hospitalized COVID-19 Patients
Gilead Sciences revealed new data from three retrospective studies that suggest its antiviral drug Veklury (remdesivir) not only reduces...
Gilead’s HIV Pipeline Targets Needs & Advances Public Health
Gilead Sciences has revealed a range of positive data from its HIV research pipeline, showcasing its innovative treatment strategies....
Unique Thyroid Cancer Tests: New Hope Unveiled
In the rapidly evolving landscape of medical research, particularly in the realm of cancer treatment, the development and application...
AbbVie, OSE Partner for Novel Anti-Inflammatory Antibody
AbbVie Inc. and OSE Immunotherapeutics SA have announced a strategic partnership to develop OSE-230, a monoclonal antibody in the...
Your New Guide to Validate Clinical Trial DHTs
The advent of sensor-based Digital Health Technologies (sDHTs) is transforming the landscape of clinical research and patient care. I...
SCRI & AstraZeneca Forge Alliance for Cancer Research Tech
Sarah Cannon Research Institute (SCRI), a global leader in conducting community-based clinical trials, has announced a collaboration with AstraZeneca...
FDA Priority Review for Epcoritamab in Refractory Lymphoma
Genmab A/S and AbbVie have received Priority Review from the FDA for epcoritamab-bysp, a bispecific antibody for the treatment...